United Therapeutics Corp
UTHR307.450USD
-1.770-0.57%
Market hours （ET）Quotes delayed by 15 min
13.90BMarket Cap
11.48P/E TTM
More Details of United Therapeutics Corp Company
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Company Info
Ticker SymbolUTHR
Company nameUnited Therapeutics Corp
IPO dateJun 17, 1999
CEODr. Martine A. Rothblatt
Number of employees1305
Security typeOrdinary Share
Fiscal year-endJun 17
Address1000 Spring St
CitySILVER SPRING
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20910
Phone13016089292
Websitehttps://www.unither.com/
Ticker SymbolUTHR
IPO dateJun 17, 1999
CEODr. Martine A. Rothblatt
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
-0.06%
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
+29.50%
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
1.22K
+93.65%
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
-0.06%
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
749.60M
94.36%
Rest of World
44.80M
5.64%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Other
65.89%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Other
65.89%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.79%
Investment Advisor/Hedge Fund
37.76%
Hedge Fund
9.20%
Pension Fund
4.79%
Individual Investor
1.76%
Research Firm
1.73%
Bank and Trust
1.43%
Sovereign Wealth Fund
1.24%
Venture Capital
0.46%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
2023Q2
1068
46.82M
99.96%
-3.45M
2023Q1
1055
47.11M
101.08%
-1.09M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
4.44M
9.84%
+15.26K
+0.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.48M
9.93%
+12.87K
+0.29%
Mar 31, 2025
Avoro Capital Advisors LLC
2.67M
5.93%
-85.30K
-3.09%
Mar 31, 2025
State Street Global Advisors (US)
2.23M
4.95%
+30.71K
+1.40%
Mar 31, 2025
Renaissance Technologies LLC
2.11M
4.67%
+17.60K
+0.84%
Mar 31, 2025
Wellington Management Company, LLP
2.03M
4.49%
-437.48K
-17.76%
Mar 31, 2025
AQR Capital Management, LLC
908.45K
2.01%
-67.00K
-6.87%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.22M
2.71%
+85.70K
+7.53%
Mar 31, 2025
LSV Asset Management
902.32K
2%
-6.40K
-0.70%
Mar 31, 2025
Invesco Capital Management LLC
376.17K
0.83%
+246.08K
+189.17%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Biotechnology & Genome ETF
4.45%
First Trust NASDAQ Pharmaceuticals ETF
3.62%
Formidable Fortress ETF
3.24%
First Trust NYSE Arca Biotechnology Index Fund
3.21%
Franklin Genomic Advancements ETF
3%
SPDR S&P Biotech ETF
2.53%
Inspire Faithward Mid Cap Momentum ETF
2.48%
Invesco Pharmaceuticals ETF
2.47%
Invesco S&P MidCap Quality ETF
2.41%
Alger Russell Innovation ETF
2.09%
View more
Invesco Biotechnology & Genome ETF
Proportion4.45%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.62%
Formidable Fortress ETF
Proportion3.24%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.21%
Franklin Genomic Advancements ETF
Proportion3%
SPDR S&P Biotech ETF
Proportion2.53%
Inspire Faithward Mid Cap Momentum ETF
Proportion2.48%
Invesco Pharmaceuticals ETF
Proportion2.47%
Invesco S&P MidCap Quality ETF
Proportion2.41%
Alger Russell Innovation ETF
Proportion2.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
